应用说明:在线浊度测量用于监测细胞培养收获液的澄清效率
Application Note - In-line Turbidity Measurement to Monitor Clarification Efficiency in Cell Culture Harvests
一篇应用说明聚焦在线浊度测量在细胞培养收获液澄清效率监测中的应用。原文未给出具体机构、药品、文件编号、版本或批次信息。
News|Articles|November 19, 2026
Related to this article
November 19th, 2026
Mazen Noureddin, MD, MHSc, of Houston Methodist Hospital discusses phase 2 data for GSK's once-monthly FGF21 analog efimosfermin presented at The Liver Meeting 2026 and what the findings mean for ongoing phase 3 trials in MASH and compensated cirrhosis.
November 19th, 2026
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
November 19th, 2026
In the first part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains which early patient responses led to the dostarlimab study behind Jemperli's rectal cancer approval, and why mismatch repair-deficient tumors are so visible to the immune system.
November 19th, 2026
Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.
November 19th, 2026
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
November 19th, 2026
DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.
November 19th, 2026
A second cereblon E3 ligase modulator from the Evotec and Bristol Myers Squibb degrader partnership is set to begin phase 1 testing in 2027.
November 18th, 2026
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
来源:BioPharm International · biopharminternational.com






